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Background: Although chronic obstructive pulmonary disease (COPD) has been
considered a disease of Caucasian men, recent data show mortality rising faster
among women and African-Americans. Some have suggested these groups are more
susceptible to tobacco smoke. We examined this issue in our own population of COPD
patients.
Methods: Beginning in March 2003 we prospectively developed a COPD research
database to facilitate recruitment for clinical trials. Enrollees are recruited from
clinics and paid advertising and their demographics, medical/smoking histories, and
spirometric data are recorded. We examined the smoking histories and pulmonary
function of enrollees over 45, with X20 pack-years of smoking, FEV1/FVC (forced
expiratory volume forced vital capacity) o0.70, and a race-adjusted post-
bronchodilator FEV1o80%. The primary outcome was the loss of lung function per
pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (%
predicted FEV1100)/pack-years.
Results: A total of 585 patients enrolled during the study period and 330 met our
inclusion criteria. Caucasians were older than African-Americans (63 vs. 58,
P ¼ 0:0003) and had more pack-years of smoking (57 vs. 43, P ¼ 0:0003). There
were no differences in lung function or bronchodilator reversibility among the racial
or gender subgroups. Caucasians had less loss of lung function per pack-year smokedElsevier Ltd. All rights reserved.
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Susceptibility to tobacco smoke among patients with COPD 1111than African-Americans (SI ¼ 1:02% vs. 1.34%, P ¼ 0:007) and men less than
women (SI ¼ 0:98% vs. 1.21%, P ¼ 0:001). Caucasian males appeared relatively
protected from tobacco smoke (SI ¼ 0:93%), while African-American women
appeared most susceptible (SI ¼ 1:42%).
Conclusions: There are important differences in racial and gender susceptibility to
tobacco smoke among patients with COPD. African-American females appear to be at
highest risk and may benefit most from smoking cessation.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is
currently the 4th leading cause of death in the
United States and mortality continues to increase.1
Although COPD has long been considered a disease
of the white male, data from the last 25 years show
that US death rates have risen more rapidly among
Caucasian and African-American women and in the
year 2000, more women than men died of the
disease.2
The changing demographics of COPD have been
attributed in part to temporal changes in smoking
habits and certainly the popularity of cigarette
smoking rose later among women than among
men.3 However, some authors have suggested that
women and African-Americans may also be more
susceptible to the damaging effects of tobacco
smoke.4–7 This possibility is of critical importance
as the prevalence of cigarette smoking is rising
fastest in young women and in the developing
world.8 Although the World Health Organization
(WHO) has already estimated that by the year 2020
COPD will be the 3rd leading cause of death
worldwide, its impact may be underestimated if
women and non-Caucasians are truly at higher risk
for the disease.9
This concept of differential susceptibility to
tobacco smoke has been controversial and studies
have shown mixed results.4–7,10 In 2000, Vollmer
published an analysis of eight previously performed
National Heart, Lung, and Blood Institute studies
that gathered data on gender, pulmonary function,
smoking status, and race.10 The authors developed
two models to address the relationship between
smoking and lung function. Although a consistent,
dose-related decline in forced expiratory volume
(FEV1) was observed across all subgroups, there
were no significant differences in the effects of
cigarette smoking between Caucasians and African-
Americans or between men and women. The study
did suggest that among African-Americans, men
may be more susceptible than women and that
Asian/Pacific Islanders may be relatively protected.
One limitation to this and other population-based
studies is that they have included all smokersdespite the fact that only 15–20% of regular
smokers develop significant COPD. In their retro-
spective review of end-stage COPD patients,
Chatila et al. attempted to address this limitation
by examining smoking habits in a group of suscep-
tible smokers.4 They examined smoking histories in
80 Caucasian and 80 African-American patients who
presented for lung transplantation or lung volume
reduction surgery at their institution. Despite
similarly poor lung function, African-Americans
and women presented at an earlier age and with
fewer pack-years of smoking than did Caucasians
and males.
The results of these two studies are not mutually
exclusive as it could be hypothesized that genetic,
biologic, or behavioral differences between racial
or gender groups not only determine their initial
susceptibility to tobacco smoke but also place some
at risk for more progressive disease.
We aimed to examine our own population of
susceptible smokers to determine the relationships
between gender, race, and lung function.Materials and methods
Patient population
Beginning in March 2003, our group has prospec-
tively developed a database of smokers to facilitate
the recruitment of patients for clinical trials of
COPD. Current or former smokers are recruited
from paid advertising and clinics. Volunteers
complete a database-specific study visit during
which baseline demographics as well as medical
and smoking histories are obtained. Pre- and post-
bronchodilator spirometry is also performed and
subjects are reimbursed for their time. To be
eligible for database entry, patients must have at
least a 15 pack-year history of smoking (calculated
as lifetime mean pack-years) and an FEV1/FVC
(FVC: forced vital capacity) ratio o75%. As of
January 2005, we have enrolled almost 600
patients.
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the database if they fulfilled the following inclusion
criteria: Age 445 years, X20 pack-years of smok-
ing, FEV1/FVC ratioo0.70, and a race-adjusted
post-bronchodilator FEV1o80% of the predicted
value. A race-adjusted FEV1o 80% was chosen to
select patients with a minimum Stage IIa disease
according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines.16
Pulmonary function tests
All patients underwent pulmonary function testing
according to American Thoracic Society (ATS)
guidelines.11 Post-bronchodilator results are re-
ported as percent predicted according to the
published estimates of Crapo for Caucasians.12 We
adjusted the predicted values for African-Ameri-
cans by multiplying by 0.88 as was done in the
National Emphysema Treatment Trial and by
others.4,13,14 Bronchodilator reversibility was de-
fined according to ATS standards as an increase in
FEV1 of X200mL and X12%.
11
Outcomes and statistics
The primary outcome for the study was the
Susceptibility Index (SI) which we defined as the
loss of lung function (measured in race-adjusted %
predicted FEV1) per pack-year smoked. The race
and gender specific SIs were calculated according
to the formula:
SI ¼ ½%Predicted post-bronchodilator FEV1  100:
Pack-years smoked
This analysis presumes that each subject’s base-
line FEV1 would be normal (100% predicted) with-Table 1 Patient characteristics.
Characteristics African-A
Age, years 5879
Male gender, number (%) 28 (56)
Pack-years smoked 43718
Current smoker, number (%) 17 (34)
FEV1/FVC 0.5370.
FEV1 (% predicted) 51717
Self-reported COPD, number (%) 22 (44)
Self-reported asthma, number (%) 7 (14)
Taking short acting beta agonists, number (%) 32 (64)
Short acting anticholinergics, number (%) 14 (28)
Long acting beta agonists, number (%) 9 (18)
Long acting anticholinergics, number (%) 1 (2)
Inhaled corticosteroids, number (%) 10 (20)
Mean values are followed by standard deviation.out the damaging effects of cigarette smoke. The SI
is therefore designed to quantify the lung damage
that has occurred in each subject as a result of
cigarette smoking. Importantly, this study is cross-
sectional in design and although the SI is reported
as loss of lung function per pack-year smoked it
cannot be interpreted as an annual rate of decline
in lung function.
Differences between African-Americans and Cau-
casians and between men and women were
compared using the chi square test for categorical
variables and the Student t-test for continuous
variables. For comparisons between the four
race–gender subgroups one-way analysis of var-
iance (ANOVA) testing with the Tukey HSD test was
used. A P value o0.05 was considered significant.Results
Patient demographics and lung function
A total of 330 patients met our inclusion criteria. Of
these, there were 172 Caucasian males, 106
Caucasian females, 28 African-American males,
and 22 African-American females. There were also
2 Hispanic patients but they were excluded from
the analysis due to the small number.
Table 1 shows the demographics, lung function,
and baseline medication use for the study popula-
tion. Caucasians were older than African-Americans
(5 years) and had heavier smoking histories (14
pack-years). There were no differences between
the two groups in terms of FEV1, the number of
current smokers, or in the frequency of self-
reported asthma or COPD. The FEV1/FVC ratio
was statistically lower among Caucasians though
the clinical difference was small (0.49 vs. 0.53).mericans (n ¼ 50) Caucasians (n ¼ 278) P value
6379 0.0003
172 (62) 0.57
57726 0.0003
108 (39) 0.62
1 0.4970.1 0.02
51717 0.95
118 (43) 1.0
26 (9) 0.45
163 (59) 0.58
83 (30) 0.92
75 (27) 0.24
2 (1) 0.77
77 (28) 0.34
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respiratory medications between the racial groups.
Figure 1 shows the age, smoking history, and FEV1
for each of the race–gender subgroups. There was
no difference in age between Caucasian men and
Caucasian women (64 vs. 60, P40:05); however,
Caucasian males were older than African-American
males (64 vs. 57, Po0:01) and African-American
females (64 vs. 58, Po0:01). Caucasian males also
had more pack-years of smoking than any of the
other subgroups (16–22 pack-years, Po0:05). There
were no differences in pack-years smoked among
the other subgroups. There were also no differ-
ences in lung function among any of the subgroups
with all meeting criteria for moderately severe to
severe obstruction based on ATS criteria.0
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Figure 1 Age, smoking histories, and lung function (FEV1)
for each of the racial and gender subgroups. *Caucasian
males were older than African-American men (Po0:01)
and African-American women (Po0:01). There was no
difference in age between Caucasian males and females
(P40:05). yCaucasian males smoked more than Caucasian
females (Po0:05), African-American males (Po0:01),
and African-American females (Po0:01). There were no
differences in lung function among the subgroups
[ANOVA, Tukey HSD test].
Table 2 Bronchodilator responsiveness.
Fraction Reversible #
Caucasian males 60/172 (35)
Caucasian females 27/106 (25)
African-American males 6/28 (21)
African-American females 9/22 (41)
There were no statistically significant differences among the g
reversibility or in the mean bronchodilator response.Bronchodilator reversibility
Table 2 shows the mean bronchodilator response for
each racial and gender subgroup. Overall, 31% of
the patients in our study had a greater than 12% and
200mL increase in their FEV1 after the administra-
tion of bronchodilator. There were no statistically
significant differences in the fraction of patients
exhibiting bronchodilator reversibility or in the
mean bronchodilator response among the sub-
groups.
Susceptibility indices
Figure 2 shows the SIs for Caucasians vs. African-
Americans and for men vs. women. Caucasians had
less loss of lung function per pack-year smoked than
African-Americans (1.02%/pack-year vs. 1.34%/
pack-year, P ¼ 0:007). Similarly, the loss of lung
function among men was less than that among
women (0.98%/pack-year vs. 1.21%/pack-year,
P ¼ 0:001).
Figure 3 shows the SI for each of the race-gender
subgroups. Caucasian men had the smallest loss of
lung function per pack-year smoked (0.93%/pack-
year) though this was not statistically different
than Caucasian women (1.17%/pack-year). Afri-
can-American men lost lung function at a 38% faster
rate than Caucasian males though African-American
women exhibited the largest change, losing lung
function 55% faster than Caucasian men (1.42%/
pack-year). There were no statistically significant
differences in the calculated SI when the non-
Caucasian/male subgroups were compared to one
another.Discussion
Our data argue that there are important differ-
ences in susceptibility to tobacco smoke among
racial and gender subgroups with obstructive lung
disease. Caucasian men appear relatively pro-/Total (%) Mean bronchodilator response (%)
12.9
14.0
11.5
15.5
roups in the fraction of patients exhibiting bronchodilator
ARTICLE IN PRESS
-1.02 +/- 0.58
-1.34 +/- 0.73
-0.98 +/- 0.57
-1.21 +/- 0.65
-2.5
-2
-1.5
-1
-0.5
0
Su
sc
ep
tib
ili
ty
 In
de
x 
(S
D)
Caucasians African
Americans
Males Females
*
†
Figure 2 Susceptibility Indices (SI). The SI represents the
change in lung function (race-adjusted % predicted FEV1)
per pack-year smoked as calculated by the formula
(%FEV1-100%)/pack-years. *Caucasians lost lung function
at a slower rate than did African-Americans (P ¼ 0:007)
as did ymen compared to women (P ¼ 0:001) [Student’s t-
test].
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Figure 3 Susceptibility Indices (SI) for each of the racial
and gender subgroups. For the entire study population,
Caucasian males appeared least susceptible to the
effects of tobacco smoke while African-American women
were most vulnerable, losing lung function at a 55% faster
rate. Comparisons are with Caucasian males and all
other comparisons are non-significant (*40.05, yo0.05,
zo0.01) [ANOVA, Tukey HSD test].
M.T. Dransfield et al.1114tected while African-American women are particu-
larly vulnerable to the deleterious effects of
smoking on lung function. These results are
concerning as the popularity of cigarettes among
women and non-Caucasian populations across the
globe continues to increase.8 Although the COPD
epidemic is well established, projections for its
future impact may be grossly underestimated if
these disparities prove correct.
Our results are similar to those observed by
Chatila who examined racial and gender differ-ences in smoking history among patients with end-
stage COPD.4 Although no differences in lung
function were observed, women and African-Amer-
icans were younger and had smoked less than
Caucasian men. Individual data for these patients
are not available; however, an estimate of the SI for
each of Chatila’s racial and gender subgroups can
be made using their average lung function (FEV1)
and pack-years smoked. For Caucasian males who
smoked an average of 74 pack-years and whose
mean FEV1 was 29%, the calculated SI is 0.96%/
pack-year (vs. 0.93%/pack-year in our study).
When these calculations are made for the other
subgroups, a remarkably similar step-up in appar-
ent susceptibility is observed: Caucasian women
(1.24%/pack-year in the Chatila paper vs. 1.17
in ours), African-American men (1.53% vs.
1.28%), and African-American women (1.71%
vs. 1.42%). It is important to note that both these
studies were done in patients who were clearly
susceptible to the effects of cigarette smoking and
who met the current GOLD definition of COPD.16 We
are aware of no other studies that have attempted
to quantify tobacco smoke susceptibility among
patients with established obstructive lung disease.
In contrast to these data, population-based
studies have demonstrated conflicting results. As
mentioned, Vollmer found no difference in the
excess decline in FEV1 attributed to smoking
between Caucasians and African-Americans (10
vs. 7mL/year, P40:05) or between men and
women (10 vs. 8mL year, P40:05).10 In a study
of 1149 Caucasian smokers, Chen found that the
FEV1 among women smokers declined at a rate
4.1mL/pack-year faster than among male smo-
kers.5 Those results were dramatically different
from data from the Six Cities study which suggested
a 5.4mL/pack-year greater decline in FEV1 among
men.6 These inconsistencies are difficult to recon-
cile though all population-based studies may be
problematic as they have included all smokers in
their analyses despite the fact that only a fraction
of them develop significant COPD.
We believe it would be naı¨ve to assume that
tobacco susceptibility for all racial and gender
subgroups is the same, and when combined with
Chatila’s observations, our data argue strongly that
this is not the case. The incidence of the only
currently known genetic risk factor for COPD,
alpha-1 antitrypsin deficiency, is higher among
Caucasians than African-Americans.17 There are
numerous other proteins including other proteases
(metalloproteinases), anti-oxidants (glutathione-s-
transferase), detoxifying enzymes (microsomal ep-
oxide hydrolase), and cytokines (TNF-a, IL-8) that
may play a role in the pathogenesis of COPD.18 It is
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proteins that predispose to COPD will be evenly
distributed among racial groups. In fact, a recent
study found that certain haplotypes of the COPD
candidate gene CLCA1, which codes for a protein
regulating airway mucous production, were com-
mon among Japanese COPD patients but not among
Egyptians with the disease.19
There also appear to be racial and gender
differences in airway reactivity which has long
been considered a risk factor for the development
of COPD.20 Joseph and colleagues have shown that
African-American children with asthma have higher
IgE levels and greater methacholine reactivity than
do Caucasian children.21 Similarly, women enrolled
in the Lung Health Study had increased bronchial
hyperresponsiveness as compared to male partici-
pants.22 This heightened airway reactivity may
disproportionately increase the risk of COPD among
African-Americans and women who smoke. Other
early life factors such as lower respiratory tract
infections, exposure to pollution, and nutritional
status may also have unequal effects on the lung
function of racial or gender subgroups.23
It could be argued that our results and Vollmer’s
population-based data are not mutually exclu-
sive.10 If there are unique genetic, biologic, or
behavioral factors that determine the initial risk for
the development of obstructive airways disease,
there may separate factors that then affect the
rate of decline of FEV1. Therefore, while all
smokers may be at comparable risk for the
development of obstructive lung disease, African-
Americans and women who develop COPD may be
particularly susceptible to progressive disease.
Our study has several limitations. First, although
the data were prospectively obtained, referral and
survivor bias may have influenced the population
enrolled in the database. African-Americans repre-
sented 15% of the entire study population which is
somewhat less than the 25% in our metropolitan
area and the state of Alabama.24 It is possible that
database patients may have more severe disease
than other African-Americans in the community.
Although this is a possible explanation for our
results, the same bias should have affected the
Caucasian male population as well. Similarly, if a
population of Caucasian men with early and severe
airways disease existed, and these men had died at
a young age, then our database would misrepresent
the overall susceptibility of the group.
A second potential limitation is that we did not
attempt to control for baseline medication usage
and no wash-out period was required prior to
spirometry. Prior studies of asthmatics suggest that
inhaled steroids and other controller medicationsare used less often in African-Americans than they
are in Caucasians.25 In our study, the frequency of
inhaled corticosteroid and long-acting bronchodi-
lator usage was similar between the racial groups
and thus this potential bias likely had little effect.
The effects of no washout period were minimized
by the use of the post-bronchodilator FEV1.
A third limitation is that we could not correct the
SI for potential confounding variables that may
affect lung function including occupational or
environmental exposure to dusts and other noxious
particles as this data was not available. We do not
believe, however, that a study of this size would
allow for a meaningful multivariate analysis. Chatila
and his colleagues attempted to examine the
influence of urban vs. suburban living (as a measure
of environmental dust exposure) on the severity of
COPD in their population.4 Although they were
unable to document an effect in their small study,
the possibility that dust exposure or even socio-
economic status may underlie the apparent racial
differences in susceptibility to tobacco smoke
cannot be ignored. Only larger studies, which we
would strongly favor, would allow definitive conclu-
sions about the validity of our observations.
We did not specifically eliminate patients with
self-reported asthma from our study. This was based
on the potential inaccuracy of self-reported diag-
noses and a significant bias against physician
diagnosis of COPD among women smokers.26 Several
facts argue against the possibility that our study
results were affected by differences in asthma
prevalence and severity amongst the subgroups.
First, the mean bronchodilator responsiveness and
fraction of patients with a significant response is
comparable to that reported in other studies of
COPD.15,27,28 Second, although a single test of
bronchodilator reversibility is not a reliable way to
differentiate asthma and COPD, our results did not
change when non-reversible patients were examined
alone. In that analysis, Caucasian males again
exhibited the smallest loss of lung function per
pack-year smoked while African-American women
exhibited the largest decline (SI ¼ 0:97% vs.
1.62%, Po0:01). Lastly, there were no differences
in the fraction of patients who reported a history of
asthma among any of the subgroups.
More research is needed to determine the basis
of our findings. The observed racial and gender
differences may be due to multiple factors includ-
ing genetic determinants, other exposures, or
behavior. It is also possible that there are differ-
ences in the biology of COPD among subpopulations
that may not only affect their susceptibility to the
disease but provide unique opportunities to inter-
vene. Although no pharmacologic agent has been
ARTICLE IN PRESS
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possible that such a benefit could have been missed
in African-Americans and women as these groups
have been underrepresented in clinical trials. Our
data do argue for more aggressive efforts at
smoking cessation among African-American women.Acknoledgments
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